These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 31597712)

  • 21. Characterization of Site-Specifically Conjugated Monomethyl Auristatin E- and Duocarmycin-Based Anti-PSMA Antibody-Drug Conjugates for Treatment of PSMA-Expressing Tumors.
    Lütje S; Gerrits D; Molkenboer-Kuenen JD; Herrmann K; Fracasso G; Colombatti M; Boerman OC; Heskamp S
    J Nucl Med; 2018 Mar; 59(3):494-501. PubMed ID: 29146698
    [TBL] [Abstract][Full Text] [Related]  

  • 22. EV20‑sss‑vc/MMAF, an HER‑3 targeting antibody‑drug conjugate displays antitumor activity in liver cancer.
    D'Agostino D; Gentile R; Ponziani S; Di Vittorio G; Dituri F; Giannelli G; Rossi C; Marzullo L; Giansanti F; De Laurenzi V; Iacobelli S; Ippoliti R; Capone E; Sala G
    Oncol Rep; 2021 Feb; 45(2):776-785. PubMed ID: 33416143
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Monomethyl auristatin E-conjugated anti-EGFR antibody inhibits the growth of human EGFR-positive non-small cell lung cancer.
    Li Z; Wang M; Yu D; Luo W; Fang J; Huang C; Yao X
    Cancer Chemother Pharmacol; 2019 Jul; 84(1):61-72. PubMed ID: 31037333
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tunable cytotoxic aptamer-drug conjugates for the treatment of prostate cancer.
    Powell Gray B; Kelly L; Ahrens DP; Barry AP; Kratschmer C; Levy M; Sullenger BA
    Proc Natl Acad Sci U S A; 2018 May; 115(18):4761-4766. PubMed ID: 29666232
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Novel Affibody-Auristatin E Conjugate With a Potent and Selective Activity Against HER2+ Cell Lines.
    Sochaj-Gregorczyk AM; Serwotka-Suszczak AM; Otlewski J
    J Immunother; 2016; 39(6):223-32. PubMed ID: 27227324
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeted Drug Delivery with an Integrin-Binding Knottin-Fc-MMAF Conjugate Produced by Cell-Free Protein Synthesis.
    Currier NV; Ackerman SE; Kintzing JR; Chen R; Filsinger Interrante M; Steiner A; Sato AK; Cochran JR
    Mol Cancer Ther; 2016 Jun; 15(6):1291-300. PubMed ID: 27197305
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An EGFR-targeting antibody-drug conjugate LR004-VC-MMAE: potential in esophageal squamous cell carcinoma and other malignancies.
    Hu XY; Wang R; Jin J; Liu XJ; Cui AL; Sun LQ; Li YP; Li Y; Wang YC; Zhen YS; Miao QF; Li ZR
    Mol Oncol; 2019 Feb; 13(2):246-263. PubMed ID: 30372581
    [TBL] [Abstract][Full Text] [Related]  

  • 28. EV20-mediated delivery of cytotoxic auristatin MMAF exhibits potent therapeutic efficacy in cutaneous melanoma.
    Capone E; Lamolinara A; D'Agostino D; Rossi C; De Laurenzi V; Iezzi M; Iacobelli S; Sala G
    J Control Release; 2018 May; 277():48-56. PubMed ID: 29550398
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Site-Specific Conjugation of Auristatins onto Engineered scFv Using Second Generation Maleimide to Target HER2-positive Breast Cancer in Vitro.
    Aubrey N; Allard-Vannier E; Martin C; Bryden F; Letast S; Colas C; Lakhrif Z; Collinet N; Dimier-Poisson I; Chourpa I; Viaud-Massuard MC; Joubert N
    Bioconjug Chem; 2018 Nov; 29(11):3516-3521. PubMed ID: 30352511
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characterization of ABBV-221, a Tumor-Selective EGFR-Targeting Antibody Drug Conjugate.
    Phillips AC; Boghaert ER; Vaidya KS; Falls HD; Mitten MJ; DeVries PJ; Benatuil L; Hsieh CM; Meulbroek JA; Panchal SC; Buchanan FG; Durbin KR; Voorbach MJ; Reuter DR; Mudd SR; Loberg LI; Ralston SL; Cao D; Gan HK; Scott AM; Reilly EB
    Mol Cancer Ther; 2018 Apr; 17(4):795-805. PubMed ID: 29483208
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synthesis, characterization, and targeted chemotherapy of SCT200-linker-monomethyl auristatin E conjugates.
    Hu X; Jiang H; Bai W; Liu X; Miao Q; Wang L; Jin J; Cui A; Liu R; Li Z
    Eur J Med Chem; 2021 Apr; 216():113297. PubMed ID: 33677351
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lysosomal trafficking and cysteine protease metabolism confer target-specific cytotoxicity by peptide-linked anti-CD30-auristatin conjugates.
    Sutherland MS; Sanderson RJ; Gordon KA; Andreyka J; Cerveny CG; Yu C; Lewis TS; Meyer DL; Zabinski RF; Doronina SO; Senter PD; Law CL; Wahl AF
    J Biol Chem; 2006 Apr; 281(15):10540-7. PubMed ID: 16484228
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of HER2-targeted affibody conjugates loaded with auristatin- and maytansine-derived drugs.
    Yin W; Xu T; Ding H; Zhang J; Bodenko V; Tretyakova MS; Belousov MV; Liu Y; Oroujeni M; Orlova A; Tolmachev V; Gräslund T; Vorobyeva A
    J Control Release; 2023 Mar; 355():515-527. PubMed ID: 36773960
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antibody-Drug Conjugates (ADCs) Derived from Interchain Cysteine Cross-Linking Demonstrate Improved Homogeneity and Other Pharmacological Properties over Conventional Heterogeneous ADCs.
    Behrens CR; Ha EH; Chinn LL; Bowers S; Probst G; Fitch-Bruhns M; Monteon J; Valdiosera A; Bermudez A; Liao-Chan S; Wong T; Melnick J; Theunissen JW; Flory MR; Houser D; Venstrom K; Levashova Z; Sauer P; Migone TS; van der Horst EH; Halcomb RL; Jackson DY
    Mol Pharm; 2015 Nov; 12(11):3986-98. PubMed ID: 26393951
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antitumor activity of a 5T4 targeting antibody drug conjugate with a novel payload derived from MMAF via C-Lock linker.
    Shi B; Wu M; Li Z; Xie Z; Wei X; Fan J; Xu Y; Ding D; Akash SH; Chen S; Cao S
    Cancer Med; 2019 Apr; 8(4):1793-1805. PubMed ID: 30843650
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anti-tubulin drugs conjugated to anti-ErbB antibodies selectively radiosensitize.
    Adams SR; Yang HC; Savariar EN; Aguilera J; Crisp JL; Jones KA; Whitney MA; Lippman SM; Cohen EE; Tsien RY; Advani SJ
    Nat Commun; 2016 Oct; 7():13019. PubMed ID: 27698471
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Preclinical Efficacy of Anti-RON Antibody-Drug Conjugate Zt/g4-MMAE for Targeted Therapy of Pancreatic Cancer Overexpressing RON Receptor Tyrosine Kinase.
    Yao HP; Feng L; Weng TH; Hu CY; Suthe SR; Mostofa AGM; Chen LH; Wu ZG; Wang WL; Wang MH
    Mol Pharm; 2018 Aug; 15(8):3260-3271. PubMed ID: 29944378
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Therapeutic efficacy, pharmacokinetic profiles, and toxicological activities of humanized antibody-drug conjugate Zt/g4-MMAE targeting RON receptor tyrosine kinase for cancer therapy.
    Yao HP; Feng L; Suthe SR; Chen LH; Weng TH; Hu CY; Jun ES; Wu ZG; Wang WL; Kim SC; Tong XM; Wang MH
    J Immunother Cancer; 2019 Mar; 7(1):75. PubMed ID: 30871619
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Activating Autophagy Enhanced the Antitumor Effect of Antibody Drug Conjugates Rituximab-Monomethyl Auristatin E.
    Wang Y; Zhang X; Fan J; Chen W; Luan J; Nan Y; Wang S; Chen Q; Zhang Y; Wu Y; Ju D
    Front Immunol; 2018; 9():1799. PubMed ID: 30123222
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An antimesothelin-monomethyl auristatin e conjugate with potent antitumor activity in ovarian, pancreatic, and mesothelioma models.
    Scales SJ; Gupta N; Pacheco G; Firestein R; French DM; Koeppen H; Rangell L; Barry-Hamilton V; Luis E; Chuh J; Zhang Y; Ingle GS; Fourie-O'Donohue A; Kozak KR; Ross S; Dennis MS; Spencer SD
    Mol Cancer Ther; 2014 Nov; 13(11):2630-40. PubMed ID: 25249555
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.